Pomaglumetad

rdf:langString Pomaglumetad

rdf:langString none

rdf:langString --4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid

rdf:langString Not FDA-approved

rdf:langString C1[C@]N

rdf:langString AVDUGNCTZRCAHH-MDASVERJSA-N

rdf:langString changed

rdf:langString changed

rdf:langString Pomaglumetad (LY-404,039) is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3. Pharmacological research has focused on its potential antipsychotic and anxiolytic effects. Pomaglumetad is intended as a treatment for schizophrenia and other psychotic and anxiety disorders by modulating glutamatergic activity and reducing presynaptic release of glutamate at synapses in limbic and forebrain areas relevant to these disorders. Human studies investigating therapeutic use of pomaglumetad have focused on the prodrug LY-2140023, a methionine amide of pomaglumetad (also called ) since pomaglumetad exhibits low oral absorption and bioavailability in humans. Early human trials using this prodrug form of pomaglumetad gave encouraging results. However, pharmaceutical company Eli Lilly terminated further development of the compound in 2012 after it failed in phase III clinical trials. In September 2013, the results of a randomized, placebo-controlled clinical trial investigating the impact of adjunctive LY-2140023 on prominent negative symptoms in schizophrenia was published and failed to demonstrate any benefit. In 2015, exclusively licensed LY-2140023 (the prodrug) for further development, having identified "a meaningful subset of patients who showed significantly improved outcomes".